Skip to main content

Advertisement

SpringerLink
Log in

Sick and Tired: Mood, Fatigue, and Inflammation in Cancer

  • Complex Medical-Psychiatric Issues (MB Riba, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Cancer patients commonly experience depression and fatigue before, during, and after treatment. Symptoms can be debilitating, and the risks associated with unrecognized or inadequately treated depression are substantial. Inflammation may be important in the genesis of depression and fatigue in cancer patients; potential neurobiological mechanisms of inflammation-related behavioral symptoms are reviewed. Randomized studies of pharmacologic treatments for depression in cancer populations are limited, but available data are generally encouraging. Studies of pharmacologic treatments for cancer-related fatigue have been more numerous but with mixed results. A practical approach to pharmacologic treatment of depression and fatigue in cancer patients involves weighing the potential risks and benefits of specific agents, including potential for adverse or advantageous side effects. Progress in understanding the neurobiological mechanisms underlying inflammation-related behavioral symptoms will provide opportunities for the development of novel and targeted treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Results from the 2012 National Survey on Drug Use and Health: Mental Health Findings. 2013 ed. Rockville, MD, Substance Abuse and Mental Health Services Administration; 2013.

  2. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74. Most comprehensive analysis to date on prevalence of depression in cancer populations.

    Article  PubMed  Google Scholar 

  3. Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326–7.

    Article  CAS  PubMed  Google Scholar 

  4. Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20:1907–17.

    Article  Google Scholar 

  5. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40:1797–810.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Breitbart W, Rosenfeld B, Pessin H, Kaim M, Funesti-Esch J, Galietta M, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA J Am Med Assoc. 2000;284:2907–11.

    Article  CAS  Google Scholar 

  7. Koornstra RH, Peters M, Donofrio S, van den Borne B, de Jong FA. Management of fatigue in patients with cancer—a practical overview. Cancer Treat Rev. 2014;40:791–9.

    Article  PubMed  Google Scholar 

  8. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat. 2007;105:209–19.

    Article  PubMed  Google Scholar 

  9. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12:123–37.

    Article  CAS  PubMed  Google Scholar 

  10. Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin N Am. 2009;29:247–64.

    Article  Google Scholar 

  11. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:971–82.

    Article  CAS  Google Scholar 

  12. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.

    Article  CAS  PubMed  Google Scholar 

  13. Endicott J. Measurement of depression in patients with cancer. Cancer. 1984;53:2243–9.

    CAS  PubMed  Google Scholar 

  14. Kathol RG, Mutgi A, Williams J, Clamon G, Noyes Jr R. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry. 1990;147:1021–4.

    Article  CAS  PubMed  Google Scholar 

  15. Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med. 1984;46:199–212.

    Article  CAS  PubMed  Google Scholar 

  16. Koenig HG, George LK, Peterson BL, Pieper CF. Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry. 1997;154:1376–83.

    Article  CAS  PubMed  Google Scholar 

  17. Li M, Rodin G. Depression. In: Levenson JL, editor. Textbook of psychosomatic medicine. Arlington: American Psychiatric Publishing, Inc; 2011.

    Google Scholar 

  18. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007;21:374–83.

    Article  CAS  PubMed  Google Scholar 

  20. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012;73:1128–38.

    Article  CAS  PubMed  Google Scholar 

  22. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–6.

    Article  CAS  PubMed  Google Scholar 

  23. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2002;26:643–52.

    Article  CAS  Google Scholar 

  24. Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M, et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2001;24:531–44.

    Article  CAS  Google Scholar 

  25. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 1996;711:163–74.

    Article  CAS  PubMed  Google Scholar 

  26. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, et al. 2013. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38:1609–16. This study provides compelling pre-clinical data regarding the neurobiological mechanisms of PIC induced behavioral symptoms, particularly with regard to kynurenine pathway metabolites and glutamate neurotransmission.

    Article  CAS  Google Scholar 

  27. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445–52.

    Article  CAS  PubMed  Google Scholar 

  28. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008;5:15.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Hines DJ, Choi HB, Hines RM, Phillips AG, MacVicar BA. Prevention of LPS-induced microglia activation, cytokine production and sickness behavior with TLR4 receptor interfering peptides. PLoS One. 2013;8:e60388.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry. 2012;73:993–1001.

    Article  PubMed  Google Scholar 

  31. Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep. 2008;10:258–64.

    Article  PubMed  Google Scholar 

  32. Iacovides A, Andreoulakis E. Bipolar disorder and resembling special psychopathological manifestations in multiple sclerosis: a review. Curr Opin Psychiatry. 2011;24:336–40.

    Article  PubMed  Google Scholar 

  33. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57.

    Article  CAS  PubMed  Google Scholar 

  34. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41. This study is the only of its kind to assess antidepressant response to a TNF-a inhibitor as the primary outcome measure, in patients with treatment resistant depression. Though the overall study was negative, there were direct associations between baseline CRP and improvement in depressive symptoms among patients treated with infliximab.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35.

    Article  CAS  PubMed  Google Scholar 

  36. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014. This systematic review and meta-analysis of anti-inflammatory treatments compared to placebo finds an overall benefit for the treatment of depression with anti-inflammatory treatments.

  37. Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, McGuffin P. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014. This is a novel and important study, identifying differential response to antidepressant treatments depending upon baseline inflammation (as measured by CRP level).

  38. Bower JE. Cancer-related fatigue-mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014. This is an elegant and comprehensive review of cancer-related fatigue, including detailed and thoughtful discussions of potential neurobiological mechanisms, the interaction with inflammation, and a review of treatments.

  39. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–93.

    Article  CAS  PubMed  Google Scholar 

  40. Clevenger L, Schrepf A, Christensen D, DeGeest K, Bender D, Ahmed A, et al. Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain Behav Immun. 2012;26:1037–44.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Cho HJ, Kivimaki M, Bower JE, Irwin MR. Association of C-reactive protein and interleukin-6 with new-onset fatigue in the Whitehall II prospective cohort study. Psychol Med. 2013;43:1773–83.

    Article  CAS  PubMed  Google Scholar 

  42. Tookman AJ, Jones CL, DeWitte M, Lodge PJ. Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2008;16:1131–40.

    CAS  Google Scholar 

  43. Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:1852–9.

    Article  CAS  Google Scholar 

  44. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:3076–82.

    Article  CAS  Google Scholar 

  45. Aan Het Rot M, Zarate Jr CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72:537–47.

    Article  Google Scholar 

  46. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.

    Article  CAS  PubMed  Google Scholar 

  47. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress and anxiety. 2013;30:297–306.

    Article  CAS  Google Scholar 

  48. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405–14.

    CAS  PubMed  Google Scholar 

  49. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597–606.

    Article  CAS  PubMed  Google Scholar 

  50. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry. 2014;19:791–800.

    Article  CAS  PubMed  Google Scholar 

  51. Wu CW, Chen YC, Yu L, Chen HI, Jen CJ, Huang AM, et al. Treadmill exercise counteracts the suppressive effects of peripheral lipopolysaccharide on hippocampal neurogenesis and learning and memory. J Neurochem. 2007;103:2471–81.

    Article  CAS  PubMed  Google Scholar 

  52. Capuron L, Pagnoni G, Demetrashvili MF, Lawson DH, Fornwalt FB, Woolwine B, et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2007;32:2384–92.

    Article  CAS  Google Scholar 

  53. Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, et al. Metabolic correlates of levodopa response in Parkinson’s disease. Neurology. 2001;57:2083–8.

    Article  CAS  PubMed  Google Scholar 

  54. Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, et al. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon Alfa administration. Arch Gen Psychiatry. 2012;69:1044–53. This study evaluates hypotheses regarding the neurocircuitry involved in PIC induced behavioral symptoms, and strengthens the evidence that dopaminergic function and the basal ganglia are involved in the behavioral response to PICs.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229. This is an excellent review of the neurobiological mechanisms of PIC induced behavioral symptoms.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Laoutidis ZG, Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013;13:140. This is the most comprehensive meta-analysis to date assessing the efficacy of antidepressant treatment for depressive symptoms in cancer patients.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Rayner L, Price A, Evans A, Valsraj K, Higginson IJ, Hotopf M. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev. 2010:Cd007503.

  58. Rayner L, Price A, Evans A, Valsraj K, Hotopf M, Higginson IJ. Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med. 2011;25:36–51.

    Article  PubMed  Google Scholar 

  59. Lydiatt WM, Bessette D, Schmid KK, Sayles H, Burke WJ. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol Head Neck Surg. 2013;139:678–86. This study demonstrates that antidepressant treatment can prevent depression in patients undergoing treatment for head and neck cancer.

    Article  PubMed  Google Scholar 

  60. Hart SL, Hoyt MA, Diefenbach M, Anderson DR, Kilbourn KM, Craft LL, et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst. 2012;104:990–1004.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008;100:1155–66.

    Article  CAS  PubMed  Google Scholar 

  62. Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116:3513–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manag. 2011;41:761–7.

    Article  CAS  Google Scholar 

  64. Bruera E, Yennurajalingam S, Palmer JL, Perez-Cruz PE, Frisbee-Hume S, Allo JA, et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:2421–7.

    Article  CAS  Google Scholar 

  65. Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3673–9.

    Article  CAS  Google Scholar 

  66. Lasheen W, Walsh D, Mahmoud F, Davis MP, Rivera N, Khoshknabi DS. Methylphenidate side effects in advanced cancer: a retrospective analysis. Am J Hosp Palliat Care. 2010;27:16–23.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996;37:57–62.

    Article  CAS  PubMed  Google Scholar 

  68. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906–14.

    Article  CAS  PubMed  Google Scholar 

  69. Booij L, van der Does AJ, Haffmans PM, Spinhoven P, McNally RJ. Acute tryptophan depletion as a model of depressive relapse: behavioural specificity and ethical considerations. Br J Psychiatry J Ment Sci. 2005;187:148–54.

    Article  Google Scholar 

  70. Young SN. Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects. J Psychiatry Neurosci. 2013;38:294–305.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem. 2006;139:655–62.

    Article  CAS  PubMed  Google Scholar 

  72. Takikawa O, Tagawa Y, Iwakura Y, Yoshida R, Truscott RJ. Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice. Adv Exp Med Biol. 1999;467:553–7.

    Article  CAS  PubMed  Google Scholar 

  73. O’Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009;14:511–22.

    Article  PubMed Central  PubMed  Google Scholar 

  74. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry. 2008;13:717–28.

    Article  CAS  PubMed  Google Scholar 

  75. Barrientos RM, Sprunger DB, Campeau S, Higgins EA, Watkins LR, Rudy JW, et al. Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuroscience. 2003;121:847–53.

    Article  CAS  PubMed  Google Scholar 

  76. Lotrich FE, Albusaysi S, Ferrell RE. Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-alpha treatment. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38:985–95.

    Article  CAS  Google Scholar 

  77. Dwyer JM, Duman RS. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry. 2013;73:1189–98.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Fernandez F, Adams F, Holmes VF, Levy JK, Neidhart M. Methylphenidate for depressive disorders in cancer patients: an alternative to standard antidepressants. Psychosomatics. 1987;28:455–61.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Jennifer L. Kruse and Thomas B. Strouse declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, 300 Medical Plaza, Rm 2273, Los Angeles, CA, 90095, USA

    Jennifer L. Kruse

  2. Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, 757 Westwood Plaza, Rm 4230B, Los Angeles, CA, 90095, USA

    Thomas B. Strouse

Authors
  1. Jennifer L. Kruse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas B. Strouse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer L. Kruse.

Additional information

This article is part of the Topical Collection on Complex Medical-Psychiatric Issues

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kruse, J.L., Strouse, T.B. Sick and Tired: Mood, Fatigue, and Inflammation in Cancer. Curr Psychiatry Rep 17, 16 (2015). https://doi.org/10.1007/s11920-015-0555-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-015-0555-3

Keywords

Search

Navigation